Floatz logo

ANASTROZOLE

Invasive Breast Carcinoma

Jonsson Comprehensive Cancer CenterSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

56 Active assets in the Invasive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
University of California, San Francisco
Phase 4BBB
Letrozole
Emory University
Phase 4BBB
EXEMESTANE
University of California, San Francisco
Phase 4BBB
FULVESTRANT
Massachusetts General Hospital
Phase 2BB
Carboplatin
Baylor Breast Care Center
Phase 3BB

View all 50 →

Same molecule, other indications

ANASTROZOLE is also rated in:

hormone receptor-positive breast cancerActive
BBB
Indicative · Phase 4
74 / 100
View asset →
hypogonadotropic hypogonadismDormant
BBB
Indicative · Phase 4
73 / 100
View asset →
female breast carcinomaActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →